Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses alterations to the immune ecosystem and bone marrow microenvironment (BME) in patients with immunoglobin light chain (AL) amyloidosis. He emphasizes the significance of targeting the BME in AL amyloidosis for optimal treatment response. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.